Articles On Cynata Therapeutics (ASX:CYP)

Title Source Codes Date
Check Up: Neuren close to FDA drug approval and Compumedics fires up Aussie factory for medical wearables

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

Stockhead CYP 15 hours ago
Check Up: Sustainable Nutrition riding high and Singular Health branches out from… health

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Stockhead CYP 2 weeks ago
Cynata edges closer to diabetic ulcer clinical trial

Cynata Therapeutics has taken a vital step to conducting a clinical trial on its Cymerus product used to treat diabetic foot ulcers, as it looks to enter a market that could be worth US$10 billion by 2027.

The West CYP 3 weeks ago
Webinar on Healthcare Innovations for Sustainable Future by Kalkine Media on October 21, 2021

SYDNEY, Oct. 16, 2021 /PRNewswire/ — Ensuring healthy lives and promoting physical and mental well-being is essential to sustainable development. Currently, the world is facing a global health crisis unlike any other. Global health has i...

FNArena CYP 1 month ago
Cynata gets go-ahead for respiratory illness trial

Clinical-stage biotechnology company, Cynata Therapeutics has received a regulatory tick of approval to continue unchanged its ‘MEND’ clinical trial which is evaluating the company’s proprietary mesenchymal stem cell product in treating pat...

The West CYP 2 months ago
Closing Bell: ASX gains to close out the week as US default fears ease

The ASX had a positive end to the week with the ASX 200 gaining 0.87% today taking its weekly gain to 1.9%. All sectors gained with the best being resources which gained nearly 1.7%. Australia’s rise was in line with the broader Asia-Pacifi...

Stockhead CYP 2 months ago
ASX Health Stocks: Immuron jumps 19pc after lead COVID-19 drug benefits published in major journal

The ASX 200 health stocks index (XHJ) had risen by 0.30% at the time of writing, compared to the broader ASX 200 index which is up by 0.74%. Immuron (ASX:IMC) jumped 19% this morning, after announcing a recent publication of the potential a...

Stockhead CYP 2 months ago
Cynata Enters into a New Strategic Partnership with Fujifilm

Key highlights Cynata and Fujifilm have entered into a new strategic partnership which includes detailed and agreed core terms for Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata’s Cymerus the...

FNArena CYP 2 months ago
Cynata seals partnership for US stem cell therapy push

Biotechnology company Cynata Therapeutics has sealed a partnership agreement with Fujifilm as it moves towards a commercial manufacturing deal for its proprietary Cymerus stem cell therapy products and eyes an accelerated push into the all-...

The West CYP 2 months ago
Peer-reviewed journal highlights Cynata stem cell treatment

Biotechnology company Cynata Therapeutics has received high-level coverage of its work on stem cell therapies for heart attacks with a well-known peer-reviewed scientific journal highlighting the successful trial use of its trademark Cymeru...

The West CYP 2 months ago
Cynata Therapeutics announces publication of new paper

Cell therapy company Cynata Therapeutics (ASX:CYP) has announced that a scientific paper describing the use of its Cymerus mesenchymal stem cells in a model of myocardial infarction has been published in the peer-reviewed journal Cy...

BiotechDispatch CYP 2 months ago
Cynata clocks up more patents for stem cell technology

ASX-listed clinical-stage biotechnology group Cynata Therapeutics is set to notch up yet another patent for its proprietary Cymerus mesenchymal stem cells technology. The company says it has now received the nod from the Patent Office of th...

The West CYP 2 months ago
Hidden Gems Webinar Recap – CYP, AT1, NSB & KZA

ShareCafeHidden Gems Webinar Recap – CYP, AT1, NSB & KZA Catch up on the full webinar with presentations from Cynata Therapeutics (ASX: CYP), Atomo Diagnostics (ASX: AT1), NeuroScientific (ASX: NSB) & Kazia Therapeutics (ASX: KZA)...

ShareCafe CYP 3 months ago
Cell based therapeutic product platform

ShareCafeCell based therapeutic product platform Dr Ross Macdonald – Managing Director and Chief Executive Officer – Cynata Therapeutics Limited is an Australian stem cell and regenerative medicine company that is developing a therapeut...

ShareCafe CYP 3 months ago
Check Up: Dimerix and ImpediMed announced breakthroughs, while earnings dominate news flow in August

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

Stockhead CYP 3 months ago
Cynata racks up North American patents

ASX-listed clinical-stage stem cell and regenerative medicine group Cynata Therapeutics’ proprietary Cymerus mesenchymal stem cells technology has been impressing the patent overseers in North America as the company looks set to secure yet...

The West CYP 3 months ago
Cynata set to clinch US stem cell patent

Clinical-stage stem cell and regenerative medicine group Cynata Therapeutics looks to be on the verge of landing a prized patent from the US for its proprietary Cymerus mesenchymal stem cells technology. The company says it expects to recei...

The West CYP 3 months ago
Check up: Rhinomed (ASX:RNO) soars with NSW COVID contract, and genetic testing fails to impress

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

Stockhead CYP 3 months ago
Check Up: Hexima roars 70pc on clinical trials, while Bionomics heads for a US dual listing

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

Stockhead CYP 4 months ago
Check Up: Rhythm (ASX:RHY) plans US expansion, the US$1.5b dog dermatitis market and data dumps drive stocks down

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

Stockhead CYP 4 months ago
Check up: A mixed bag for ASX health stocks as FDA decides fates at the flip of a coin

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Stockhead CYP 5 months ago
ScoPo’s Powerplays: ‘Go long equities’ as Nanosonics, Antisense, Volpara to benefit from V-shaped recovery

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Theme of the week Healthcare fi...

Stockhead CYP 5 months ago
Cynata nears clinical trial for diabetic ulcer treatment

Cynata Therapeutics has secured relevant ethics approval for a clinical trial on its Cymerus product for the treatment of diabetic foot ulcers as it looks to enter a market that could be worth US$10 billion within a decade.

The West CYP 5 months ago
Cynata makes key appointment in diabetic foot ulcer fight

Cynata Therapeutics has appointed leading clinical research organisation Dataphram Australia to manage and assist in an upcoming clinical trial for its Cymerus product for treating foot ulcers as it looks to enter a market that could be wor...

The West CYP 5 months ago
ASX edges lower; Afterpay, Qantas fall

Summary The S&P/ASX 200 dropped 7.70 points or 0.11% to 7,300 by afternoon. The market sentiments were dented by coronavirus lockdowns and increased restrictions.  Redbubble was the top percentage gainer, while Gold Road Resources...

Kalkine Media CYP 5 months ago
Check Up: As Alzheimer’s grabs the spotlight, these ASX biotech stocks also impressed

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

Stockhead CYP 5 months ago
New breakthrough in stem cells research paves the way for ASX regenerative medicine stocks

A recent article published in the Advance Science magazine discussed research by Monash University that uncovered a new technique to alter the shape of individual stem cells, which could potentially speed up recovery times for bone replacem...

Stockhead CYP 6 months ago
Escrow Watch: Some of the hottest IPOs of the last two years are releasing restricted securities this month

Escrow Watch is Stockhead’s monthly recap of the ASX companies that are releasing shares currently in escrow (also known as restricted securities) over the coming weeks. ASX shares in escrow are “locked away” and not listed on the bourse so...

Stockhead CYP 6 months ago
Cynata-TekCyte alliance to advance diabetic foot ulcer treatment

Cynata Therapeutics has nailed an exclusive global licence agreement with TekCyte, a leading developer and manufacturer of thin-film polymer coatings, as it looks to conduct a clinical trial for the treatment of diabetic foot ulcers using T...

The West CYP 6 months ago
ASX dream run continues, hits a new high; energy stocks lead 

Summary The ASX 200 continued gaining momentum on Thursday, hitting a fresh record high. The market sentiment got a lift after trade balance and retail sales both rose in April. Energy stocks emerge as top gainers, owing to a rise in...

Kalkine Media CYP 6 months ago
Invion led a group of ASX cancer stocks up after promising news

It was a good day for some of ASX-listed cancer therapy stocks yesterday, with three companies releasing seperate announcements that sent their share prices higher. Cancer therapy stocks Invion (ASX:IVX), Immutep (ASX:IMM), and Imugene (ASX...

Stockhead CYP 6 months ago
Cynata recruits first respiratory patient for stem cells clinical trial

ASX-listed clinical-stage stem cell and regenerative medicine group, Cynata Therapeutics has enrolled the first patient suffering from respiratory failure for a clinical trial that it has called “MEND” testing its proprietary Cymerus mesenc...

The West CYP 6 months ago
Five ASX stocks making a buzz today

Summary Frontier Resources has successfully completed its landowner MRA Warden’s hearing as part of the renewal process of its wholly owned tenement. Vection Technologies has achieved a milestone of completing its first public hospital...

Kalkine Media CYP 6 months ago
ASX Gains Amid Choppy Trade, Healthcare, Energy Stocks in High Spirits

Summary The ASX 200 trades higher by 15.20 points or 0.22% to 7045.50 at the close, led by gains in heavyweight healthcare and energy stocks. Retail player Kogan.Com and gold miner Silver Lake Resources are top performing stocks on the...

Kalkine Media CYP 6 months ago
Capital Raisings Recap: Nearly $10 billion has already been raised in 2021

The capital raisings boom on the ASX is continuing in 2021 with nearly $10 billion raised in the first four months of the year. Across 325 deals, ASX companies have raised $9.878 billion in capital amidst IPOs, placements and rights issues....

Stockhead CYP 7 months ago
Cynata seeks patients for osteoarthritis and respiratory trials

ASX-listed clinical-stage stem cell and regenerative medicine group, Cynata Therapeutics is looking for patients who are suffering from osteoarthritis in the knees and severe respiratory distress for two separate clinical trials currently u...

The West CYP 7 months ago
Dimerix (ASX:DXB) advances COVID-19 Phase 3 study, enrols multiple patients

Summary Drug discovery company developing new therapies, Dimerix, has enrolled multiple patients in REMAP-CAP study in Europe. In the ACE2 RAS study domain, subjects will be randomised to receive one RAS blockade strategy or control....

Kalkine Media CYP 7 months ago
ScoPo’s powerplays: Look to Mach7, Volpara and IMEXHS as quarterly reports near

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week The health...

Stockhead CYP 8 months ago
Cynata extends stem cell therapy clinical trial beyond COVID-19

Cynata Therapeutics has received ethics committee approval to expand the recruitment criteria of its active “MEND” clinical trial in patients in intensive care with respiratory failure. The trial will now look beyond just patients suffering...

The West CYP 8 months ago
What’s the latest with these two Australian healthcare penny stocks – CYP, OVN

Source:Cryptographer, Shutterstock Summary Stem cell and regenerative medicine player Cynata Therapeutics will expand recruitment criteria for its active MEseNchymal coviD-19 clinical trial. Oventus medical enters into a virtual Lab i...

Kalkine Media CYP 8 months ago
Cynata COVID-19 treatment trial expanded to other respiratory illnesses

Stem cell therapeutics company Cynata's (ASX: CYP) pool of eligible patients in a COVID-19 treatment trial will be increased after the company received ethics committee approval to include those suffering from respiratory failure. The exp...

businessnewsaustralia.com CYP 8 months ago
Check Up: Oneview leads healthcare sector after ‘investor awareness’ pact

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Stockhead CYP 8 months ago
Two ASX healthcare stocks that had a strong week

Source: Guschenkova, Shutterstock Summary Medical technology player Nova Eye Medical announced the publication of positive patient follow-up data from a sub-study analysis of the LEAD trial. Cynata Therapeutics has initiated a new stu...

Kalkine Media CYP 9 months ago
Cynata to study impact of stem cell technology on mice

Having already successfully demonstrated the efficacy and safety of its proprietary stem cells on rodents with lung disease, Cynata Therapeutics is now set to embark on a new study on mice designed to find out how and why its stem cells wor...

The West CYP 9 months ago
Cynata Therapeutics announces new study of cell therapy

Cynata Therapeutics (ASX:CYP), a clinical-stage biotechnology company specialising in cell therapeutics, has announced the initiation of a new study to investigate its Cymerus mesenchymal stem cells. 

BiotechDispatch CYP 9 months ago
Cynata tests wound dressing tech for stem cell therapy delivery

Cynata Therapeutics has signed an MoU with TekCyte Pty Ltd to access its wound dressing technology in the hope of commercialising TekCyte’s proprietary surface modifications of polymer-coated dressings for the delivery of Cynata’s mesenchym...

The West CYP 9 months ago
Cynata boosts coffers with $1.4m Government grant

Cynata Therapeutics’ recent run of successful capital raisings has been bolstered by a lazy $1.39m tax refund courtesy of the Federal Government’s Research & Development Tax Incentive grant scheme, adding to its already burgeoning $24.9...

The West CYP 9 months ago
Why Cynata is hopeful its COVID treatment trial will succeed where others have failed

Cynata Therapeutics (ASX: CYP), founded by two clever stem cell researchers and one wise Australian techpreneur, is in the process of developing a treatment for COVID-19. Using its in-house stem cell technology Cymerus, the ASX-listed bio...

businessnewsaustralia.com CYP 10 months ago
Why Cynata is hopeful its COVID treatment trial will succeed where others have failed

Cynata Therapeutics (ASX: CYP), founded by two clever stem cell researchers and one wise Australian techpreneur, is in the process of developing a treatment for COVID-19. Using its in-house stem cell technology Cymerus, the ASX-listed bio...

businessnewsaustralia.com CYP 10 months ago
Are these 4 ASX medical shares set for a healthy 2021?

If 2020 taught us anything, it was the importance of quality healthcare. The COVID-19 pandemic put unprecedented demand on global health services, with many providers rising to the challenge. Healthcare has long been seen as a defensive in...

Motley Fool CYP 11 months ago